| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Protein synthesis in cells and E is specifically inhibited by streptinomycin dihydrochloride pentahydrate. Spectinomycin dihydrochloride pentahydrate (50 μg/mL) inhibits E. coli extracts quickly and reversibly. coli development and prevents the incorporation of amino acids right away [1]. With a maximal inhibition rate of 70-80% in E, streptinomycin diHClide penta Hydro (1 μg/mL or 3 μM) inhibits peptide synthesis guided by endogenous messenger RNA or MS-2 phage RNA. Coli extracts [1]. By preventing elongation factor G from attaching to the ribosome, streptinomycin diHCl pentahydrate prevents the translocation of peptidyl tRNA from the A site to the P site [2]. Residues G1064 and 01192 in 16S rRNA are particularly interacting with and may be rendered inactive by streptinomycin diHClide penta Hydro [2]. Due to its dependence on pH variations and Mg2+ content, streptinomycin diHCl pentahydrate shows splicing inhibition, which may indicate electrostatic interactions with intronic RNA [3].
|
|---|---|
| ln Vivo |
It has been demonstrated that in healthy chicks, spectinomycin dihydrochloride pentahydrate (20 mg/kg; IM; 20-100 mg/kg; 9 days) is safe [4]. The majority of the dose of specinomycin dihydrochloride pentahydrate (10 mg/kg; intravenous injection; single dose) is excreted unchanged into the urine by the kidneys [5]. Rat spectinomycin pentahydrate pharmacokinetics [5]: parameter C0 (μg/mL) AUC0-∞ (μg·h/mL) Vd (L/kg) CL (L/h/kg) MRT (h) T1/2α (h) T1/2β (h) fe CLrenal (L/h/kg) Eratio Non-compartmental analysis 44.3 16.8 0.756 0.602 0.757 / / / 0.553 0.359 1.00 Three-compartment model 37.8 15.7 0.747 0.649 1.11 / 0.2 37 0.754 19.5 //
|
| Animal Protocol |
Animal/Disease Models: Arbor Acres plus broiler chicken (15 days old) [4]
Doses: 20 mg/kg, 60 mg/kg, 100 mg/kg Route of Administration: intramuscularinjection (chest muscle) ; 9-day Experimental Results: complete blood count, biochemical parameters, histopathology, clinical signs, weight gain and feed conversion ratio (FCR) demonstrated biosafety of 20 mg/kg. Produces mild toxicity at 60 mg/kg. |
| References |
[1]. Davies J, et al. Inhibition of protein synthesis by spectinomycin. Science. 1965 Sep 3;149(3688):1096-8.
[2]. Brink MF, et al. Spectinomycin interacts specifically with the residues G1064 and C1192 in 16S rRNA, thereby potentially freezing this molecule into an inactive conformation. Nucleic Acids Res. 1994 Feb 11;22(3):325-31. [3]. Park IK, et al. Spectinomycin inhibits the self-splicing of the group 1 intron RNA. Biochem Biophys Res Commun. 2000 Mar 16;269(2):574-9. [4]. Madhura DB, et al. Pharmacokinetic profile of spectinomycin in rats. Pharmazie. 2013 Aug;68(8):675-6. [5]. Khan EA, et al. Safety evaluation study of lincomycin and spectinomycin hydrochloride intramuscular injection in chickens. Toxicol Rep. 2022 Jan 29;9:204-209. |
| Molecular Formula |
C14H24N2O7
|
|---|---|
| Molecular Weight |
332.3496
|
| CAS # |
22189-32-8
|
| Related CAS # |
Spectinomycin dihydrochloride;21736-83-4;Spectinomycin;1695-77-8
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
O1[C@]2(C(C([H])([H])[C@@]([H])(C([H])([H])[H])O[C@@]2([H])O[C@]2([H])[C@]([H])([C@@]([H])([C@@]([H])([C@@]([H])([C@@]12[H])N([H])C([H])([H])[H])O[H])N([H])C([H])([H])[H])O[H])=O)O[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~62.5 mg/mL (~126.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (100.94 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0089 mL | 15.0444 mL | 30.0888 mL | |
| 5 mM | 0.6018 mL | 3.0089 mL | 6.0178 mL | |
| 10 mM | 0.3009 mL | 1.5044 mL | 3.0089 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
